Observational studyFundamental & clinical pharmacology2026
Variability in Sertraline Pharmacokinetics in Routine Clinical Practice: Influence of Sex, Age, Body Weight, Smoking, and Co-Medication.
Observational study in Fundamental & clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the influence of sex, age, body weight, smoking habits, and co-medications on sertraline pharmacokinetics in a routine clinical setting.
methodsThis retrospective observational study analyzed 177 predominantly inpatient therapeutic drug monitoring records from 101 patients receiving sertraline as monotherapy or polytherapy. Pharmacokinetic parameters-serum concentrations (CSER), concentration-to-dose ratio (CDR), weight-normalized CDR (CDR/kg), apparent clearance (CL/F), and metabolite-to-parent ratio (N-SER/SER)-were compared across subgroups defined by sex, age (< 18; 18-65; > 65 years), BMI, smoking, and co-medications. To address the nonindependence of repeated measurements, analyses were complemented using linear mixed-effects models and a sensitivity analysis restricted to one observation per patient.
resultsDescriptive analyses suggested higher CDR/kg in males and higher CSER in elderly patients. After accounting for within-patient clustering, the increase in CDR/kg across BMI categories remained the most consistent finding, likely reflecting mathematical normalization. The higher CSER observed in elderly patients persisted in the mixed-effects model but not in the sensitivity analysis, although the direction of effect remained consistent. Sex-related differences were not robust after adjustment and were largely attributable to body weight. Smoking showed no measurable effect. Among co-medications, carbamazepine showed the most consistent pharmacokinetic signal, whereas other findings were less consistent.
conclusionElderly age may contribute to higher sertraline concentrations; however, its effect appears modest after accounting for clustering. Sex differences are largely explained by body weight, and smoking does not appear to influence pharmacokinetics. Carbamazepine showed a consistent induction pattern, whereas other co-medication findings should be considered exploratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.